UPADACITINIB AS MONOTHERAPY: A PHASE 3 RANDOMIZED CONTROLLED DOUBLE-BLIND STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE

被引：0

作者：

Smolen, J. S. ^{[1
]}

Cohen, S. ^{[2
]}

Emery, P. ^{[3
]}

Rigby, W. ^{[4
]}

Tanaka, Y. ^{[5
]}

Zhang, Y. ^{[6
]}

Friedman, A. ^{[6
]}

Othman, A. A. ^{[6
]}

Camp, H. S. ^{[6
]}

Pangan, A. L. ^{[6
]}

机构：

[1] Med Univ Vienna, Vienna, Austria

[2] Metroplex Clin Res Ctr, Dallas, TX USA

[3] Leeds NIHR BRC, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[4] Dartmouth Coll, Hanover, NH 03755 USA

[5] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka, Japan

[6] AbbVie, N Chicago, IL 60064 USA

来源：

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2019年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

223

引用

页码：S52 / S52

页数：1

共 50 条

[1] Upadacitinib As Monotherapy: A Phase 3 Randomized Controlled Double-Blind Study in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Smolen, Josef S.
Cohen, Stanley
Emery, Paul
Rigby, William F. C.
Tanaka, Yoshiya
Zhang, Ying
Friedman, Alan
Othman, Ahmed A.
Camp, Heidi S.
Pangan, Aileen L.
[J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
[2] UPADACITINIB AS MONOTHERAPY: A PHASE 3 RANDOMISED CONTROLLED DOUBLE-BLIND STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE
Smolen, J.
Cohen, S.
Emery, P.
Rigby, W.
Tanaka, Y.
Zhang, Y.
Friedman, A.
Othman, A.
Camp, H.
Pangan, A.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 67 - 68
[3] UPADACITINIB AS MONOTHERAPY: A PHASE 3 RANDOMISED CONTROLLED DOUBLE-BLIND STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE
Smolen, J. S.
Cohen, S.
Emery, P.
Rigby, W.
Tanaka, Y.
Zhang, Y.
Friedman, A.
Othman, A. A.
Camp, H. S.
Pangan, A. L.
[J]. RHEUMATOLOGY, 2019, 58
[4] Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
Smolen, Josef S.
Pangan, Aileen L.
Emery, Paul
Rigby, William
Tanaka, Yoshiya
Vargas, Juan Ignacio
Zhang, Ying
Damjanov, Nemanja
Friedman, Alan
Othman, Ahmed A.
Camp, Heidi S.
Cohen, Stanley
[J]. LANCET, 2019, 393 (10188): : 2303 - 2311
[5] A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate
Fleischmann, Roy
Pangan, Aileen L.
Mysler, Eduardo
Bessette, Louis
Peterfy, Charles
Durez, Patrick
Ostor, Andrew
Li, Yihan
Zhou, Yijie
Othman, Ahmed A.
Song, In-Ho
Genovese, Mark C.
[J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
[6] Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study (vol 393, pg 2303, 2019)
Smolen, J. S.
Pangan, A. L.
Emery, P.
[J]. LANCET, 2019, 393 (10191): : 2590 - 2590
[7] Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-Blind, Monotherapy Study in Patients with Active Rheumatoid Arthritis with Intolerance or Inadequate Response to Methotrexate
Burmester, Gerd
Lin, Yong
Patel, Rahul
van Adelsberg, Janet
Mangan, Erin
van Hoogstraten, Hubert
Bauer, Deborah
Ignacio Vargas, Juan
Lee, Eun Bong
[J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
[8] EFFICACY AND SAFETY OF SARILUMAB VERSUS ADALIMUMAB IN A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MONOTHERAPY STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH INTOLERANCE OR INADEQUATE RESPONSE TO METHOTREXATE
Burmester, G.
Lin, Y.
Mangan, E.
Van Hoogstraten, H.
Vargas, J.
Lee, E.
[J]. INTERNAL MEDICINE JOURNAL, 2017, 47 : 26 - 26
[9] Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial
Fleischmann, Roy
Pangan, Aileen L.
Song, In-Ho
Mysler, Eduardo
Bessette, Louis
Peterfy, Charles
Durez, Patrick
Ostor, AndrewJ
Li, Yihan
Zhou, Yijie
Othman, Ahmed A.
Genovese, Mark C.
[J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71 (11) : 1788 - 1800
[10] A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING UPADACITINIB MONOTHERAPY TO MTX MONOTHERAPY IN MTX-NAIVE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
van Vollenhoven, R.
Takeuchi, T.
Pangan, A. L.
Friedman, A.
Mohamed, M. F.
Chen, S.
Rischmueller, M.
Blanco, R.
Xavier, R. M.
Strand, V.
[J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S4 - S4

← 1 2 3 4 5 →